How to Buy Zoetis Stock (ZTS): Pet Drugs Spun Off From Pfizer

2026-11-12

How to Buy Zoetis Stock (ZTS): Pet Drugs Spun Off From Pfizer

Because Zoetis lists its common stock on the New York Stock Exchange under the ticker ZTS, a brokerage account with US market access is all the purchase requires. The company began as Pfizer's animal health unit and became fully independent in 2013; in 2025 its products for pets made up about 70% of revenue, and two pet franchises, Simparica and Apoquel, brought in roughly 28% between them. Below: what Zoetis sells, how to place the order, and the risks its filings flag.

How to Buy Zoetis Stock (ZTS): Pet Drugs Spun Off From Pfizer: key points at a glance

What Does Zoetis Do?

Zoetis develops, makes and sells medicines, vaccines and diagnostics for animals: dogs, cats and horses on the companion animal side, and cattle, swine, poultry, fish and sheep on the livestock side. It sells in more than 100 countries.

Zoetis was incorporated in Delaware in July 2012 and before that was a business unit of Pfizer. Its shares started trading on the NYSE on 1 February 2013, and the initial public offering, about 19.8% of the shares, closed five days later. On 24 June 2013 an exchange offer let Pfizer shareholders swap Pfizer stock for Zoetis stock, which disposed of Pfizer's entire stake.

Several familiar names in veterinary medicine are Zoetis products. Apoquel, approved in 2013, was the first Janus kinase inhibitor for veterinary use and treats itching in allergic dogs; Cytopoint, licensed in the US in 2016, was the first canine monoclonal antibody. Simparica Trio, a monthly chewable, protects dogs against fleas, ticks, heartworm and some intestinal worms. Librela (dogs) and Solensia (cats) are monthly antibody injections for osteoarthritis pain, and in 2025 the EU and Canada approved Lenivia and Portela, versions given every three months.

Zoetis says its business "is the largest based on revenue in the animal health industry." The 10-K names four primary competitors: Boehringer Ingelheim Animal Health, Merck Animal Health, Elanco Animal Health and IDEXX Laboratories. Merck's own shares are covered in our Merck stock guide.

How Zoetis Makes Money

Most pet products are "primarily available by prescription through a veterinarian." Zoetis sells them to vets or to veterinary distributors, and the clinic sells to the owner. The largest single customer, a US veterinary distributor, accounted for about 16% of 2025 revenue. The two reporting segments are geographic: the United States brought in 54% of 2025 revenue and International 45%. By product category:

Category Share of 2025 revenue Examples
Parasiticides 25% Simparica, Revolution
Vaccines 21% Vanguard, Fostera, Poulvac
Dermatology 19% Apoquel, Cytopoint
Anti-infectives 11% Ceftiofur line, Draxxin
Pain and sedation 9% Librela, Solensia
Other pharmaceutical 7% Cerenia
Animal health diagnostics 5% Vetscan analyzers

Percentages are worked out from the 10-K revenue note; contract manufacturing and other lines make up the rest.

Revenue is concentrated. Simparica and Simparica Trio contributed about 16% and Apoquel about 12%; with Cytopoint, Librela and the ceftiofur antibiotics, the top five product lines made up about 42%. Among livestock species, cattle is the largest line, at about 16% of revenue.

Growth in 2025 came mostly from price. Revenue rose 2%, or 3% excluding currency; the 10-K attributes about 4 points to price, while the sale of the medicated feed additive portfolio, completed on 31 October 2024, took away about 3 points. Companion animal revenue grew 5%, livestock fell 5%.

ZTS Stock at a Glance

Feature ZTS
Exchange New York Stock Exchange
Ticker ZTS
Share class Common stock, its sole Section 12(b) registration
Listed since 1 February 2013
Sector Animal health: medicines, vaccines and diagnostics
Index membership S&P 500
Headquarters Parsippany, New Jersey
Incorporated Delaware, July 2012
Financial year January to December
Payouts Quarterly cash dividend; share repurchase program with no stated expiration date
SEC identifier CIK 1555280

Anything that changes by the minute, from price to dividend yield, is on the Zoetis stock page on Bitbase.

How to Buy Zoetis Stock

Zoetis files a 10-K, so no depositary receipt is involved: the NYSE line is the share itself. Five steps:

1. Pick the broker. Any firm that routes orders to the NYSE will do; abroad, check which entity holds your assets and who supervises it.

2. Complete onboarding. Expect identity checks and, for non-US individuals, IRS Form W-8BEN, which the IRS says to "submit … when requested by the withholding agent or payer."

3. Move money in. Paying in a currency other than US dollars means a conversion, and the rate applied can cost more than the commission.

4. Confirm the security. Typing ZTS should bring up Zoetis Inc. common stock on the NYSE, the one class on the 10-K cover.

5. Set the order. FINRA calls a market order the one that "provides the most certainty that your order will be executed," while a limit order executes only "at or better than a specified price." Some brokers sell fractions of a share, but FINRA notes that "as a fractional share owner, you might not have shareholder voting rights."

Living outside the US. The IRS says that "most types of U.S. source income received by a foreign person are subject to U.S. tax of 30%," unless a tax treaty sets a lower rate. Zoetis pays a quarterly dividend, so the withholding applies to each payment, and your home country may tax it again.

Through a fund. ZTS is in the S&P 500, so an index fund such as SPY gives you a sliver of Zoetis alongside the rest of the index.

What Moves ZTS Stock

The itch franchise and its rivals. Dermatology was 19% of 2025 revenue, and it is the line the 2026 filings single out. In the third quarter of 2026, US segment revenue fell 6% and US companion animal revenue 8%; the 10-Q says the "key dermatology franchise faced heightened competitive pressure and persistent macroeconomic-driven price sensitivity."

Generics. US sales of the cattle antibiotic Draxxin have fallen 66% since 2021, the first year of generic competition, and in 2026 generics reached Convenia and Cerenia.

Pain antibodies. Librela was a top-five product line in 2025, yet lower Librela sales held back US growth that year and again in 2026. The three-month Lenivia, launched in Great Britain in the third quarter of 2026, is the next step in the same category.

Animal disease. Outbreaks can close export markets, but they also raise demand for treatments: the 10-Q ties stronger US cattle sales in 2026 partly to the New World screwworm outbreak, for which Simparica Trio received an Emergency Use Authorization for dogs.

Currency. About 42% of 2025 revenue was in foreign currencies, which cut reported growth by 1 point that year.

Competition, Generics and Safety Questions at Zoetis

Of the risk factors in Item 1A, these bear most directly on a ZTS share:

A few brands. "Our results of operations are dependent upon the success of our top-selling products."

Safety signals. "Our products are subject to unanticipated safety, quality or efficacy concerns," which the 10-K says could lead to "product recalls, label changes or other measures."

Cheaper alternatives. "Generic and other products may be viewed as more cost-effective than our products."

Buyer power. "Consolidation of our customers and distributors could negatively affect the pricing of our products."

The Pfizer link. Some intellectual property is still licensed from Pfizer, whose rights as licensor could limit what Zoetis develops.

Litigation. A securities class action filed on 27 May 2026 in federal court in New York alleges misleading statements about demand for Librela, Simparica Trio, Apoquel and Cytopoint; Zoetis says it has "substantial defenses." The case is at an early stage.

Above these sit the risks of the share itself: a single stock concentrates your money in one business, and "no assurance is given that we will pay any dividends."

Reading Zoetis Filings Without Getting Tripped Up

The filings sit on EDGAR under CIK 1555280: the annual 10-K, quarterly 10-Qs and event-driven 8-Ks; the 2026 earnings-release 8-Ks came on 12 February, 7 May, 6 August and 5 November. In the 10-K, Item 1 lists products and competitors, Item 1A the risks, and the revenue note splits sales by species and product category.

One trap concerns comparisons across years. From 1 January 2026, Zoetis stopped reporting its non-US subsidiaries on a one-month lag, and the 10-Q says 2025 periods "have been recast." Figures in the 2025 10-K therefore will not match the comparatives in 2026 reports.

Note too that "operational" growth strips out currency, and "organic operational" growth also strips out acquisitions and divestitures.

The Item 5 performance graph sets ZTS against the S&P 500 and the S&P 500 Pharmaceuticals Index, so the company benchmarks itself against drugmakers; its former parent is covered in our Pfizer stock guide. For prices, use the ZTS page linked earlier; Bitbase's US stock directory has pages for other listed names.

Zoetis Stock FAQ

Can I buy Zoetis stock with crypto?

Not directly. ZTS shares are bought in US dollars through a broker, so crypto would first have to be sold for cash, which may be taxable. Owning ZTS means holding a registered share with a vote and a dividend, which is one of the ways a share differs from a crypto asset.

Does Zoetis pay a dividend?

Yes, a quarterly cash dividend, and the amount declared for 2026 was higher than in 2025. The board decides each payment, and the dividend 8-Ks give the amount and dates.

Was Zoetis part of Pfizer?

Yes. It was Pfizer's animal health business until 2013, listed on the NYSE that February, and the June 2013 exchange offer ended Pfizer's ownership.

What exchange is ZTS listed on, and is it in the S&P 500?

The New York Stock Exchange, since 1 February 2013. It is an S&P 500 constituent and appears in State Street's SPY holdings for 9 November 2026.

Conclusion

Zoetis is a bet on the habits of pet owners and farmers: how much households spend at the vet, whether its itch and pain antibodies hold their ground against new rivals, and how fast generics reach older drugs. Its filings supply the gauges: top-five product share, US companion animal growth and the securities case. Read the latest 10-K and 10-Q, with the 2026 recast in mind, before deciding what share of your savings one animal health company deserves.

Related reading

Other Bitbase articles on this topic:

Disclaimer: This article is educational content from Bitbase Academy, provided for information only. It explains what a company or fund does and how the instruments referenced here differ from one another; it does not constitute investment, trading, tax, or financial advice, and it is neither a recommendation nor an endorsement of any security, token, or trading strategy. A tokenized stock is issued by a third party and is designed to give economic exposure to an underlying asset: it is not a share, it carries no shareholder rights, and it depends on the issuer's structure, eligibility rules, and redemption terms, which the issuer can change. Perpetual futures are leveraged derivatives that hold no underlying asset and can be liquidated, and trading hours, product availability, and eligibility differ by instrument and by jurisdiction and can change at any time. Written as of November 2026; verify everything yourself through company filings, the issuer's own documentation, and the product pages of the venue you trade on.

References

[1] Zoetis Form 10-K for 2025 (SEC EDGAR) www.sec.gov

[2] Zoetis 2025 Form 10-K, XBRL cover page (SEC EDGAR) www.sec.gov

[3] Zoetis 2025 Form 10-K, revenue by product (XBRL, SEC EDGAR) www.sec.gov

[4] Zoetis Form 10-Q for the third quarter of 2026 (SEC EDGAR) www.sec.gov

[5] Zoetis third quarter 2026 results release, Form 8-K Exhibit 99.1 (SEC EDGAR) www.sec.gov

[6] Zoetis Form 10-K for 2013: IPO and separation from Pfizer (SEC EDGAR) www.sec.gov

[7] State Street SPY daily holdings (as of 9 November 2026) www.ssga.com

[8] FINRA: Order types www.finra.org

[9] FINRA: Investing in fractional shares www.finra.org

[10] IRS: NRA withholding www.irs.gov

[11] IRS: About Form W-8 BEN www.irs.gov

Related Articles

More Recommendations